BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 19, 2024
Home
»
Newsletters
» BioWorld Asia
BioWorld Asia
Aug. 9, 2006
View Archived Issues
Paion Accelerates Phase III Program For Desmoteplase
Paion AG is accelerating the Phase III development program for its lead compound, the recombinant plasminogen activator Desmoteplase, which is in development for treating acute ischemic stroke. (BioWorld International)
Read More
Serum Institute Invests In Lipoxen; Firms Sign Deal
Read More
Neutralizing Antibody Has Promise Versus HIV Strains
Read More
Biosecurity Rises Higher Up On Europe's Agenda
Read More
Chasing Next-Generation Stents, Axordia Working With Lombard
Read More
After Knocking Out Genes, Rye Grass Pollen Made Sneeze-Free
Read More
Immutep Initiating Phase I IMP321 Breast Cancer Trial
Read More
Diamyd Medical Enters First GAD65 Out-Licensing Deal
Read More
Other News To Note
Read More